News
04-08-2013, 03:03 AM
Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).
More... (http://www.news-medical.net/news/20130408/Sorrento-Therapeutics-IGDRASOL-to-present-updates-on-Cynviloq-at-Nanomedicine-2013-meeting.aspx)
More... (http://www.news-medical.net/news/20130408/Sorrento-Therapeutics-IGDRASOL-to-present-updates-on-Cynviloq-at-Nanomedicine-2013-meeting.aspx)